195 related articles for article (PubMed ID: 22310287)
1. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Ferguson J; Arozarena I; Ehrhardt M; Wellbrock C
Oncogene; 2013 Jan; 32(1):86-96. PubMed ID: 22310287
[TBL] [Abstract][Full Text] [Related]
2. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
El Touny LH; Vieira A; Mendoza A; Khanna C; Hoenerhoff MJ; Green JE
J Clin Invest; 2014 Jan; 124(1):156-68. PubMed ID: 24316974
[TBL] [Abstract][Full Text] [Related]
3. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
4. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Chua KN; Kong LR; Sim WJ; Ng HC; Ong WR; Thiery JP; Huynh H; Goh BC
Oncotarget; 2015 Oct; 6(30):29991-30005. PubMed ID: 26358373
[TBL] [Abstract][Full Text] [Related]
6. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Mitchell C; Hamed HA; Cruickshanks N; Tang Y; Bareford MD; Hubbard N; Tye G; Yacoub A; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2011 Aug; 12(3):215-28. PubMed ID: 21642769
[TBL] [Abstract][Full Text] [Related]
8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
9. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith MP; Ferguson J; Arozarena I; Hayward R; Marais R; Chapman A; Hurlstone A; Wellbrock C
J Natl Cancer Inst; 2013 Jan; 105(1):33-46. PubMed ID: 23250956
[TBL] [Abstract][Full Text] [Related]
10. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
11. Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.
Aftimos PG; Wiedig M; Langouo Fontsa M; Awada A; Ghanem G; Journe F
Int J Oncol; 2013 Sep; 43(3):919-26. PubMed ID: 23835698
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Gangadhar TC; Clark JI; Karrison T; Gajewski TF
Invest New Drugs; 2013 Jun; 31(3):769-73. PubMed ID: 23151808
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
14. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
15. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
[TBL] [Abstract][Full Text] [Related]
16. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
[TBL] [Abstract][Full Text] [Related]
17. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
18. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Dry JR; Pavey S; Pratilas CA; Harbron C; Runswick S; Hodgson D; Chresta C; McCormack R; Byrne N; Cockerill M; Graham A; Beran G; Cassidy A; Haggerty C; Brown H; Ellison G; Dering J; Taylor BS; Stark M; Bonazzi V; Ravishankar S; Packer L; Xing F; Solit DB; Finn RS; Rosen N; Hayward NK; French T; Smith PD
Cancer Res; 2010 Mar; 70(6):2264-73. PubMed ID: 20215513
[TBL] [Abstract][Full Text] [Related]
20. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Purnell PR; Mack PC; Tepper CG; Evans CP; Green TP; Gumerlock PH; Lara PN; Gandara DR; Kung HJ; Gautschi O
J Thorac Oncol; 2009 Apr; 4(4):448-54. PubMed ID: 19240653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]